Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial…
<!-- Name:DistributionId Value:8828263 -->
<!--…
Read More...
Read More...
Browsing Tag
Nasdaq:SELB
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of…
WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company…
Read More...
Read More...
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study,…
- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of…
Read More...
Read More...